OT mobile menu

Search form


Central Nervous System Cancer Targets

Central Nervous System Cancer Targets

Many childhood brain tumors harbor potentially targetable gene mutations, according to a prospective single-institution study of more than 200 tumor samples, researchers reported in the journal Neuro-Oncology.

Researchers are reporting in the journal Cancer Research that they have identified a biomarker enzyme associated with aggressive glioma brain tumors. In addition, they have demonstrated potent efficacy in a mouse model of glioma for a small molecule inhibitor they recently developed.

A new study is suggesting that radiomic features subjected to machine learning algorithms may be able to identify imaging signatures that defined a subset of patients with recurrent glioblastoma who may gain the most benefit from antiangiogenic therapy.

A new study reveals clues on how brain tumors develop and spread, and this new information may provide valuable insight into diagnosis and treatment.

Researchers at the University of Pittsburgh have developed a sequencing test to analyze a broad spectrum of genetic alterations in central nervous system (CNS) tumors.

Dr. Marachelian and her team have demonstrated that there is a new treatment that is equivalent to a product that has been manufactured for commercial use and should be made available to patients outside of clinical trials.

Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.


Subscribe to Central Nervous System Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.